Results of the Phase 3 Clinical Pathway for Acute Coronary Syndrome in China was published in JAMA Cardiology

On April 17, 2019, JAMA Cardiology, an internationally renowned medical journal, published the results of the Phase 3 Clinical Pathway for Acute Coronary Syndrome in China (CPACS-3), led by Professor Yangfeng Wu, Honorary senior research fellow at The George Institute China and the Deputy Director of the Peking University Clinical Research Institute.

The results show that among resource-constrained Chinese hospitals, introducing a clinical pathway-based Quality of Care Improvement (QCI) initiative had no significant effect on reducing in-hospital major adverse cardiovascular events (MACE), although there were some improvements for several care process indicators of evidence-based management of acute coronary syndrome (ACS) events.

Since its launch in 2004, CPACS has been dedicated to finding methods to narrow the gap between clinical practice and guideline recommended practice of cardiovascular disease in China. It is one of the largest studies that has focused on the healthcare quality improvement for patients with ACS in China.

CPACS-3 was a 4-year multi-center cluster randomized trial that included 101 secondary hospitals and 29,346 patients with ACS in 15 provinces and cities in China. Overall, 14,809 patients were in the control ‘usual care’ group and 14,537 were in the intervention ‘QCI’ group. Rates of in-hospital MACE between the two groups is not significantly different. However, the composite score of performance indicators was significantly higher in the intervention group.

"Characterized by acute onset and high risk, ACS has a high death rate. Thus, improving quality is crucial for better prognosis" Professor Wu said, "We are regret to find the study did not achieve expected intervention effect, but we still hope that it can be served as a reference for subsequent studies.”